Evidence map›Paper›PMID 31487061›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2020

EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets.

Juraj Adamik, Sree H Pulugulla, Peng Zhang, Quanhong Sun, Konstantinos Lontos, David A Macar, Philip E Auron, Deborah L Galson

Open access · bronzeAbstract read
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Juraj AdamikDepartment of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-3604-158X
Sree H PulugullaDepartment of Biological Sciences, Duquesne University, Pittsburgh, PA, USA.ORCID 0000-0002-6474-1129
Peng ZhangDepartment of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Quanhong SunDepartment of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Konstantinos LontosDepartment of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
David A MacarDepartment of Biological Sciences, Duquesne University, Pittsburgh, PA, USA.
Philip E AuronDepartment of Biological Sciences, Duquesne University, Pittsburgh, PA, USA.ORCID 0000-0001-5749-2622
Deborah L GalsonDepartment of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-2045-8807
UPMC Hillman Cancer Center · USDuquesne University · USUniversity of Pittsburgh · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Viral and Genetic Regulation of Abnormal OCL Activity in PDR01AR057310 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GALSON, DEBORAH LYNN · 2008 to 2019
$3.6M
GFI-1 and Osteoblast Suppression in Multiple MyelomaR01AR059679 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GALSON, DEBORAH LYNN, ROODMAN, GARSON DAVID · 2010 to 2014
$1.4M
NCI NIH HHS P30 CA047904NIAMS NIH HHS R01 AR057310NIAMS NIH HHS R01 AR059679
6 · The paper itself

Abstract

Key osteoclast (OCL) regulatory gene promoters in bone marrow-derived monocytes harbor bivalent histone modifications that combine activating Histone 3 lysine 4 tri-methyl (H3K4me3) and repressive H3K27me3 marks, which upon RANKL stimulation resolve into repressive or activating architecture. Enhancer of zeste homologue 2 (EZH2) is the histone methyltransferase component of the polycomb repressive complex 2, which catalyzes H3K27me3 modifications. Immunofluorescence microscopy reveals that EZH2 localization during murine osteoclastogenesis is dynamically regulated. Using EZH2 knockdown and small molecule EZH2 inhibitor GSK126, we show that EZH2 plays a critical epigenetic role in OCL precursors (OCLp) during the first 24 hours of RANKL activation. RANKL triggers EZH2 translocation into the nucleus where it represses OCL-negative regulators MafB, Irf8, and Arg1. Consistent with its cytoplasmic localization in OCLp, EZH2 methyltransferase activity is required during early RANKL signaling for phosphorylation of AKT, resulting in downstream activation of the mTOR complex, which is essential for induction of OCL differentiation. Inhibition of RANKL-induced pmTOR-pS6RP signaling by GSK126 altered the translation ratio of the C/EBPβ-LAP and C/EBPβ-LIP isoforms and reduced nuclear translocation of the inhibitory C/EBPβ-LIP, which is necessary for transcriptional repression of the OCL negative-regulatory transcription factor MafB. EZH2 in multinucleated OCL is primarily cytoplasmic and mature OCL cultured on bone segments in the presence of GSK126 exhibit defective cytoskeletal architecture and reduced resorptive activity. Here we present new evidence that EZH2 plays epigenetic and cytoplasmic roles during OCL differentiation by suppressing MafB transcription and regulating early phases of PI3K-AKT-mTOR-mediated RANKL signaling, respectively. Consistent with its cytoplasmic localization, EZH2 is required for cytoskeletal dynamics during resorption by mature OCL. Thus, EZH2 exhibits complex roles in supporting osteoclast differentiation and function. © 2019 American Society for Bone and Mineral Research.

Indexed as

Bone ResorptionOsteoclastsAnimalsCell DifferentiationEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticMicePhosphatidylinositol 3-KinasesEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mousePhosphatidylinositol 3-KinasesCYTOSKELETAL DYNAMICSEPIGENETICSEZH2OSTEOCLASTPI3K-AKT-mTOR SIGNALING

Identifiers

PMID31487061
PMCPMC7402427
OpenAlexW2971485865

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.